Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Moxifloxacin on Gut Microbiota
NCT06462326Phase 1Completed
- Sponsor
- Zai Lab
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omadacycline in community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSI) (2 arms), sponsored by Zai Lab. Primary endpoints: Changes in the types of microbial resistomes at 3 months, Changes in the quantity of microbial resistomes at 3 months and 1 more. Started Apr 2024; status: completed.
02
Drugs
omadacycline
03
Conditions
community-acquired bacterial pneumonia (CAP)acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT06462326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462326.